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Background: Estimating survival is challenging in the terminal phase of advanced heart failure. 
Patients, families and healthcare organizations would benefit from more reliable prognostic 
tools. The Palliative Performance Scale Version 2 (PPSv2) is a reliable and validated tool used to 
measure functional performance, higher scores indicate higher functionality. It has been widely 
used to estimate survival in patients with cancer, but rarely used in patients with heart failure.  
Aim: The aim of this study was to identify prognostic cut-points of the PPSv2 for predicting 
survival among patients with heart failure receiving home hospice care. 
Methods: This retrospective cohort study included 1,114 adult patients with a primary diagnosis 
of heart failure from a not-for-profit hospice agency between January 2013 and May 2017. The 
primary outcome was survival time. A Cox proportional-hazards model and sensitivity analyses 
were used examine the association between PPSv2 scores and survival time, controlling for 
demographic and clinical variables. Receiver Operating Characteristic (ROC) curves were 
plotted to quantify the diagnostic performance of PPSv2 scores by survival time. 
Results: Lower PPSv2 scores on admission to hospice were associated with decreased median 
(IQR) survival time (PPSv2 10 = 2 (IQR: 4) days; PPSv2 20 = 3 (IQR: 6) days; PPSv2 30 = 13 
(IQR: 48) days). The discrimination of the PPSv2 at baseline for predicting death was highest at 
7 days (AUC=0.802), followed by an AUC of 0.774 at 14 days, an AUC of 0.736 at 30 days, and 
an AUC of 0.705 at 90 days.  
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Conclusions: The PPSv2 tool can be used by healthcare providers for prognostication of 
hospice-enrolled patients with heart failure who are at high risk of near-term death. It has the 
greatest utility in patients who have the most functional impairment. 
 
Journal subject terms: hospice, palliative care, heart failure, prognosis, palliative performance 
scale, end-of-life care 
 
Abbreviations:  
PPSv2: Palliative Performance Scale Version 2  
VNSNY: Visiting Nurse Service of New York  
STROBE: Strengthening the Reporting of Observational Studies in Epidemiology 
 
ICD: International Classification of Diseases 
ROC: Receiver Operating Characteristic  
AUC: Area under the curve  
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(3) Introduction  
Heart failure is a progressive disease characterized by high symptom burden that primarily 
affects older adults with multiple comorbid conditions.1 In the terminal phase (stage D), 
estimating survival is challenging because it has a nonlinear disease trajectory.2,3 As such, less 
than half of physicians accurately estimate survival,4 and the error is systematically optimistic.5  
Though national guidelines recommend using population-based risk-calculators 6-8 to estimate 
survival for patients with heart failure,8,9 these models have limited ability to prospectively 
identify the vast majority of heart failure patients who will die in the next year.2,10 
Prognostication is thus hampered by limited tools, wide variation in time-to-death between 
patients,2 and poor accuracy of clinician derived survival estimates,4,5 thus adversely affecting 
patient quality of life near the end of life.5  
 
For patients and families, knowing how much time remains is important for decision making, 
closure for personal and family matters, and shared decision making focused on patient goals of 
care.2 A clear prognosis is also informative for hospice organizations who need to allocate end-
of-life services and select therapies most consistent with a patient’s estimated survival time. To 
handle the high symptom burden at the end of life, an intensification of services is often 
necessary. Given the high error in survival estimates for patients with heart failure,4,5 having 
objective data demonstrating a high risk of mortality within a specified timeframe would be 
informative for patients, patient families, and hospice agencies alike.  
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Palliative Performance Scale Version 2 (PPSv2) has been widely utilized across palliative care 
patient populations, yet limited data is available on its prognostic value in patients with heart 
failure. The PPSv2 is a modified version of the Karnofsky Performance scale and is used to 
measure functional status in palliative care11,12 and predict survival among terminally ill 
patients.13 In the most recent review of the PPSv2, Downing and colleagues reported that it is 
highly predictive of survival in a mixed palliative care population.14 The relationship between a 
lower PPSv2 score and shorter length of survival has been reported most commonly for patients 
with cancer.15 To our knowledge this is the first study to use the PPSv2 to estimate survival time 
among home hospice heart failure patients. The purpose of this study is to identify prognostic 




Study Setting and Data Sources 
This retrospective cohort study included 1,114 adult patients with a primary diagnosis of heart 
failure served from a not-for-profit hospice agency in New York between January 2013 and May 
2017. This home hospice agency has an average daily census of more than 1,000 patients in its 
hospice program across all five New York City boroughs. The inclusion criteria for this study 
was patients with a primary diagnosis of heart failure over 18 years of age. For patients with 
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multiple episodes of hospice care during the study period (i.e. two or more admissions), the first 
episode was selected. The sample included patients with complete data on all study measures. 
 
Patient data were obtained from the electronic medical record database. This database has a 
diverse set of variables which includes socio-demographics, severity of illness, comorbid 
conditions, admission disposition, PPSv2 scores which were collected by nurses at the time of 
enrollment, and date of death or discharge from hospice services.   For patients who enrolled in 
and out of hospice on multiple occasions, we included the first episode of hospice care only. The 
home hospice agency and Columbia University Medical Center institutional review boards 
approved the conduct of this study and the study complies with the Declaration of Helsinki. The 
Strengthening the Reporting of Observational Studies in Epidemiology guidelines for the 
reporting of observational studies were followed.16  
Measures 
The primary outcome in our study was survival time. This variable was calculated as the 
difference in days between the date of hospice admission and date of death in hospice. Socio-
demographic characteristics included sex, age, race/ethnicity, insurance, marital status, the 
absence of a primary caregiver, and the absence of a healthcare proxy. International 
Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) and 10th revision 
(ICD-10) codes were used to calculate Charlson comorbidity index scores.17 Hospice referral 
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source, which distinguished those who entered hospice following a hospitalization versus non-
hospital settings, was also collected.  
 
The PPSv2 is a reliable and validated tool used to measure functional performance across five 
domains: ambulation, activity and evidence of disease, independence in self-care, oral intake, 
and level of consciousness13,18 (Table 1). The PPSv2 is divided into 11 categories between 0% 
and 100% in 10% increments, in which higher scores indicate higher functionality.13 Since 
PPSv2 scores ranged from 0-60 in this cohort, we used six discrete PPS scores (10, 20, 30, 40, 50 
and 60). For all patients the VNSNY hospice program, the PPSv2 is completed as part of a 
comprehensive admission assessment at admission to hospice care and then every two months as 
a measure of functional status and ongoing change.  
 
Data Analysis 
Means and percentages were used to describe the study population, including demographic and 
clinical characteristics, crude mortality rates by PPSv2 score. Medians and interquartile ranges 
were used to describe survival time by PPSv2 score (among patients who died in hospice), and 
differences in survival by PPSv2 were evaluated using the Kruskal-Wallis rank sum test. 
Receiver Operating Characteristic (ROC) curves were plotted for all patients to quantify the 
diagnostic performance of PPSv2 scores. Sensitivity analyses were also conducted to examine 
whether diagnostic performance of PPSv2 scores varied by survival time. A Cox proportional-
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hazards model was used to examine associations of survival time with PPSv2 scores, controlling 
for patient socio-demographic and clinical characteristics.19 Patients who were discharged alive 
from hospice were censored at the date of discharge. A p-value of 0.05 represented the threshold 
for determining statistical significance.  Survival time was top-coded to one year and censored as 
of the date of discharge if patients left hospice prior to their death.  The Kaplan–Meier event-free 
survival graphs controlled for all covariates in the regression model. All analyses were 
performed using R version 3.4.3.  
 
(5) Results 
Study Population  
The majority of home hospice patients in our analysis were female (56.6%) with a mean age of 
mean age of 86 years and had a primary caregiver (83.8%) (Table 2). All patients lived in New 
York City and were racially and ethnically diverse (22.4% Hispanic, 17.8% African American 
and 7.6% Asian). Most patients were insured through Medicare (63.4%) or Managed Medicare 
(e.g., Medicare Advantage; 29.4%) and were admitted into hospice from the hospital (53.6%). 
PPSv2 scores at admission to hospice ranged from 10 to 60. The modal PPSv2 score was 40 
(36.2% of all patients). The mean Charlson Comorbidity Index score was relatively low (2.8, 
SD=1.1). The five most frequent comorbidities among patients included renal failure (25.0%), 
type II diabetes without clinical complications (20.4%), chronic pulmonary disease (18.8%), 
dementia (16.1%), and stroke (9.5%). While the majority of patients died while under hospice 
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care (72.3%), over a quarter of patients were discharged alive (27.7%).  Among those who were 
discharged alive (n=309), the reasons for discharge included acute hospitalization (49.5%), 
elective revocation to pursue disease-directed treatments (21.0%), disqualification (16.2%), or 
transfer to another hospice or care setting (13.3%). There was minimal missing data (<5%) for 
all study measures.  
 
Percentage of Hospice Deaths and Survival Time by Palliative Performance Scale Score 
There was a higher mortality rate among patients admitted to hospice with low PPSv2 scores. 
Nearly all patients admitted to hospice with a PPSv2 score of 10 or 20 died during their hospice 
stay (96% and 92% respectively). In contrast, a smaller percentage of those admitted with PPSv2 
scores of 50 or 60 died in hospice (56% and 37% respectively) (Figure 1a).   
 
The median survival time was significantly shorter for patients with lower PPSv2 scores 
compared to those with higher PPSv2 scores at the time of admission (p<0.001). Among the 805 
patients who died in hospice, the median survival time was 2 [IQR: 4] and 3 [IQR: 6] days for 
patients admitted with a PPSv2 score of 10 and 20, compared to a median survival time of 80 
days [IQR: 152] for patients with a PPSv2 score of 60 (Figure 1b).  
 
Accuracy of PPSv2 Scores at Admission in Predicting Hospice Survival 
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While the overall predictive accuracy of the PPSv2 for our sample was modest (Area under the 
curve [AUC]=0.69), the predictive accuracy of PPSv2 scores varied according to survival time.   
The PPSv2 had greater accuracy in predicting survival within the first weeks of hospice 
enrollment (AUC for hospice survival at 7 days=0.80; 14 days=0.77; 30 days=0.74; 90 
days=0.71; 180 days=0.69).   
 
Factors Predicting Hospice Survival Time from a Multivariable Cox Proportional Hazards Model 
Results from the multivariate Cox Proportional Hazards regression predicting hospice survival 
time model indicate that PPSv2 scores on admission independently predict survival time among 
hospice patients with heart failure. Compared to those with a PPSv2 score of 60, those with 
PPSv2 scores ≤20 had particularly higher hazard of mortality; 18.6 (95% CI= 8.5 to 40.7) and 
10.2 (95% CI= 4.6 to 22.6) among hospice patients with PPSv2 scores of 10 and 20, respectively 
(Table 3). Kaplan-Meier survival curves plotted for each value of the PPSv2 using Cox 
regression estimates and average covariate values indicate a graded increase in mortality risk 
from higher to lower PPSv2 scores (Figure 3). 
 
(6) Discussion  
This is one of the largest and most recent studies in the United States to evaluate the use of the 
PPSv2 for end-of-life prognostication among patients enrolled in hospice services with a primary 
diagnosis of heart failure.  We found that the PPSv2 can be used to predict survival time for 
This article is protected by copyright. All rights reserved.
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patients with heart failure who are enrolled in hospice.  Predictive accuracy for death of the 
PPSv2 was incrementally improved among patient groups with low PPSv2 scores.  
The PPSv2 is widely used in other patient populations for end-of-life prognostication, but there 
is limited research establishing its utility in the heart failure population. The findings of this 
study support the use of the PPSv2 score at admission for estimating survival in the first 30 days 
of hospice enrollment. The diagnostic accuracy was greatest among those with low scores, 
specifically scores of 10 and 20, which correlated with a survival of under a week. This finding 
is consistent with Harrold and colleagues who reported that, among a heterogeneous cohort of 
patients enrolled in a community hospice program, PPSv2 scores are most accurate in predicting 
mortality within one week (AUC: 0.8~0.85).20 As such, the PPSv2 can be informative for 
patients and families who ask healthcare providers to predict anticipated life expectancy. Given 
the poor accuracy of clinician derived survival estimates,4,5 the PPSv2 can be used as supporting 
evidence and a “reality check” for the prognosis. The PPSv2 can also be used by hospice 
agencies to support the allocation of appropriate resources, such as more extensive symptom 
management support, to individuals for whom death is imminent.  
 
This is the largest study of patients with heart failure to report Kaplan-Meier survival curves by 
initial PPSv2 scores among cardiac home hospice patients. In this sample, there were distinct 
survival curves for each discrete value of the PPSv2 (10, 20, 30, 40, 50 and 60). Our findings 
extend observations by Lau et al21 and Downing et al14 who similarly demonstrated that survival 
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curves differed according to PPSv2 scores among a range of non-HF diagnoses. Given that the 
association between PPSv2 scores and survival may vary between different patient populations, 
our study has established normative survival data for patients with heart failure. This is critical 
for building an evidence-base that can be applied to patients with similar diagnoses and socio-
demographic characteristics.21 Finally, there are mixed perspectives on whether the PPSv2 score 
should be used as a categorical 22,23 (i.e., groups of PPSv2 scores) or discrete (i.e. individual 
PPSv2 score values) variables for prognostication. 24-26 Our study demonstrates that each PPSv2 
score has a unique trajectory of survival time and supports the value of reporting individual 
discrete scores.  
 
Patients with advanced heart failure often experience uncontrolled symptoms and rapid changes 
in their disease trajectories. Despite this, palliative care for patients with heart failure often lags 
behind that for other diseases such as cancer.27 Consistent with an American Heart Association 
guideline,2 we recommend that palliative approaches occur earlier in the disease process, ideally 
timing conversations about advance care planning between patients and providers with the initial 
diagnosis of heart failure.28,29  Given the potential for improved prognostication and low burden 
on providers, our study findings indicate that there may be utility in using PPSv2 scores at 
hospice admission. Future research steps include the evaluation of the PPSv2 as part of 
informing hospice eligibility at the time of hospital discharge. Finally, almost a quarter of the 
population dis-enrolled from hospice. This is a large and important segment of the population. 
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Future research should explore predictors of discharge in this population, including PPSv2 
scores. More research is also needed on the clinical utility of repeated PPSv2 measurements and 
whether they can be used to evaluate trajectories of change for patients. The clinical implications 
of this finding for healthcare providers within cardiac home hospice programs is that this short, 
provider completed questionnaire can be a helpful indicator of survival in the next 30 days, 
which can be extremely valuable information for patients, families, and providers.  
 
Limitations 
There are some important limitations to consider.  First, survival time is limited to the period of 
time that patients were enrolled in hospice, and does not include data for patients who were 
discharged from hospice and admitted to local hospitals. We had limited data on patient 
socioeconomic status including income and education. Another limitation is that comorbid 
conditions may be underreported in this sample. Medicare regulations changed in 2014, 
implemented in 2015, mandating that hospices code for both the terminal illness as well as other 
coexisting diagnoses which support the terminal condition. These regulations may lead to an 
underreporting of comorbid conditions, which may explain why the Charlson Comorbidity Index 
is relatively low in this sample of patients. Very few participants in our sample had PPS scores of 
60 raising questions about the validity of prognostication for scores in this range. This was also 
expected because it is a cohort of hospice enrolled patients. Finally, our data were derived from a 
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Our study demonstrates that the PPSv2 at admission to hospice has high predictive accuracy for 
survival in the first 30-day among patients with heart failure, with incremental value at lower 
PPSv2 scores. These findings provide evidence that this tool can be used to estimate time to 
death among heart failure patients enrolled in hospice, which may be helpful for patients and 
families who frequently request accurate predictions of prognosis, and for hospice agencies who 
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(11) Figure Titles and Legends 
 
Figure 1a. Death in hospice by PPSv2 scores 
Legend: Figure 1a represents the proportion of people who died in hospice by PPSv2 score at 
admission to hospice.  
 
Figure 1b: Length of survival in days by PPSv2 scores  
Legend: Figure 1b represents a box plot of the median length of survival in days by PPSv2 score 
at admission to hospice.  
 
Figure 2. Receiver Operating Characteristic (ROC) Curve by Length of Service Group 
Legend: Figure 2 displays the ROC curve predicting survival based on PPSv2 score values 
measured on hospice admission across five groups (i.e., 7 days, 14 days, 30 days, 90 days, 180 
days).  
 
Figure 3. Adjusted Kaplan-Meier survival curves from Multiple Cox Regression 
Legend: Figure 3 displays adjusted Kaplan-Meier survival curves plotted for each value of the 
PPSv2 using Cox regression estimates and average covariate values.




Table 1: Palliative Performance Scale (PPSv2) version 2 
PPS Level Ambulation Activity and Evidence of Disease Self-care Intake Conscious Level 
100% Full Normal activity & work 
No evidence of disease 
Full Normal Full 
90% Full Normal activity & work 
No evidence of disease 
Full Normal Full 
80% Full Normal activity & work 
No evidence of disease 
Full Normal or Reduced Full 
70% Reduced Unable Normal Job/Work 
Significant disease 
Full Normal or Reduced Full 




Normal or Reduced Full  
Or Confusion 




Normal or Reduced Full  
Or Confusion 
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40% Mainly in Bed Unable to do most activity 
Extensive disease 
Mainly assistance Minimal to sips Full or Drowsy 
+/- Confusion 
30% Totally Bed Bound Unable to do any activity 
Extensive disease 
Total Care Mouth care only Full or Drowsy 
+/- Confusion 
20% Totally Bed Bound Unable to do any activity 
Extensive disease 
Total Care  Full or Drowsy 
+/- Confusion 
10% Totally Bed Bound Unable to do any activity 
Extensive disease 
Total Care  Drowsy or Coma 
+/- Confusion 
0% Death - - - - 
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Table 2: Characteristics of the Study Population by PPSv2 at Admission 
Characteristics Total 10% 20% 30% 40% 50% 60% p-value 
No. of participants, (%) 1114 (100) 82 (7) 79 (7) 288 (26) 403 (36) 243 (22) 19 (2)  
Female sex 630 (57) 40 (49) 44 (56) 190 (66) 224 (56) 126 (52) 6 (32) 0.001 
Age, years         
  18 to 64 48 (4)  5 (6) 5 (6) 4 (1) 15 (3.7) 17 (7) 2 (11) <0.001   
  65 to 74  107 (10) 17 (21) 6 (8) 22 (8) 30 (7) 27 (11) 5 (26)  
  75 to 84  248 (22) 23 (28) 21 (27) 53 (18) 88 (22) 57 (24) 6 (32)  
  85 + 711 (64) 37 (45) 47 (60) 209 (73) 270 (67) 142 (58) 6 (32)  
Race/Ethnicity        0.162 
  Hispanic 250 (22) 20 (24) 17 (22) 55 (19) 96 (24) 57 (24) 5 (26)  
  Non-Hispanic Black 198 (18) 11 (13) 13 (17) 44 (15) 68 (17) 56 (23) 6 (32)  
  Non-Hispanic White 581 (52) 45 (55) 45 (57) 160 (56) 211 (52) 115 (47) 5 (26)  
  Other 85 (8)  6 (7) 4 (5) 29 (10) 28 (7) 15 (6) 3 (16)  
Marital Status        0.176 
  Not Married 756 (68) 48 (59) 50 (63) 210 (73) 269 (67) 166 (68) 13 (68)  
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  Married 358 (32) 34 (41) 29 (37) 78 (27) 134 (33) 77 (32) 6 (32)  
Primary Caregiver (none) 181 (16) 10 (12) 19 (24) 52 (18) 55 (14) 42 (17) 3 (16) 0.188 
Advanced Directives (none) 196 (18) 23 (28) 28 (35) 49 (17) 64 (16) 26 (11) 6 (32) <0.001   
Payer Source        0.356 
  Commercial/Other 44 (4)  5 (6) 4 (5) 4 (1) 19 (5) 10 (4) 1 (5)  
  Managed Medicaid 16 (1)  2 (2) 1 (1) 2 (1) 4 (1) 6 (2) 1 (5)  
  Managed Medicare 327 (29) 27 (33) 21 (27) 91 (32) 114 (28) 71 (29) 4 (21)  
  Medicaid 21 (2)  1 (1) 1 (1) 2 (1) 12 (3) 4 (2) 1 (5)  
  Medicare 706 (63) 47 (57) 52 (66) 189 (66) 254 (63) 152 (63) 12 (63)  
Charlson Comorbidity Score, mean (SD) 2.82 (1) 2.63 (1) 2.82 (1) 2.90 (1) 2.83 (1) 2.83 (1) 2.32 (1) 0.198 
Comorbidities, mean %          
  Renal failure 278 (25) 16 (20) 27 (34) 60 (21) 103 (26) 68 (28) 4 (21) 0.1 
  Type II Diabetes 227 (20) 12 (15) 11 (14) 52 (18) 97 (24) 50 (21) 5 (26) 0.119 
  Pulmonary Disease 209 (19) 4 (5) 12 (15) 54 (19) 80 (20) 55 (23) 4 (21)      0.022 
  Dementia 179 (16) 10 (12) 15 (19) 62 (22) 59 (15) 33 (14) 0 (0) 0.02 
  Stroke 106 (10) 12 (15) 9 (11) 29 (10) 36 (9) 18 (7) 2 (11) 0.445 
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Referral Source        <0.001   
  Hospital 597 (54) 70 (85) 59 (75) 150 (52) 190 (47) 116 (48) 12 (63)  
  Other Setting 517 (46) 12 (15) 20 (25) 138 (48) 213 (53) 127 (52) 7 (37)  
Discharge Reason        <0.001   
  Acute Hospitalization 153 (14) 1 (1) 2 (3) 23 (8) 69 (17) 53 (22) 5 (26)  
  Disqualification 50 (4)  0 (0) 0 (0) 9 (3) 23 (6) 16 (7) 2 (11)  
  Revocation 65 (6)  2 (2) 3 (4) 9 (3) 26 (6) 22 (9) 3 (16)  
  Transfer  41 (4)  0 (0) 1 (1) 6 (2) 18 (4) 14 (6) 2 (11)  
  Death 805 (72) 79 (96) 73 (92) 241 (84) 267 (66) 138 (57) 7 (37)  
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Table 3: Cox Proportional Hazards Model Predicting Hazard of Mortality among Hospice Patients with 
Heart Failure (N=1,114) 
Variable Unadjusted HR 
(95% CI) 
p-Value Adjusted HR 
(95% CI) 
p-Value 
 PPSv2 10% 16.48 (7.59-35.80) <.001 18.57 (8.47-40.72)  <.001 
 PPSv2 20% 11.05 (5.08-24.07) <.001 10.20 (4.61-22.57) <.001 
 PPSv2 30% 3.89 (1.84-8.26) <.001 4.18 (1.94-9.01) <.001 
 PPSv2 40% 2.51 (1.19-5.32) 0.02 2.65 (1.24-5.69) 0.01 
 PPSv2 50% 1.77 (0.83-3.78) 0.14 1.90 (0.88-4.10) 0.10 
 PPSv2 60% 1 [Reference]  1 [Reference]  
Age  1.00 (1.00-1.00) 0.58 1.00 (0.98-1.00) 0.01 
Gender      
  Female 1.03 (0.90-1.19) 0.66 1.16 (1.00-1.37) 0.07 
Race/Ethnicity      
  African American 0.60 (0.50-0.74) <.001 0.53 (0.43-0.66) <.001 
  Hispanic 0.72 (0.60-0.87) <.001 0.60 (0.49-0.73) <.001 
  Other 0.79 (0.61-1.04) 0.08 0.72 (0.55-0.95) 0.02 
Marital Status      
  Married 1 [Reference]  1 [Reference]  
  Not Married 0.86 (0.74-1.00) 0.04 0.82 (0.70-0.98) 0.03 
Primary Caregiver      
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Abbreviations: PPSv2: Palliative Performance Scale version 2; CI: Confidence Interval; HR: hazard ratio 
 
  Yes 1 [Reference]  1 [Reference]  
  No 1.20 (0.99-1.46) 0.07 1.41 (1.16-1.72) <.001 
Advance Directive      
  No 1 [Reference]  1 [Reference]  
  Yes 2.18 (1.81-2.62) <.001 2.07 (1.70-2.52) <.001 
Referral source      
  Hospital 1 [Reference]  1 [Reference]  
  Other Setting  0.80 (0.69-0.91) 0.001 0.84 (0.72-0.98) 0.02 
Payer Source      
  Medicare 1 [Reference]  1 [Reference]  
  Commercial/Other 0.869 (0.59-1.28) 0.48 0.829 (0.55-1.25) 0.37 
  Managed Medicaid 0.633 (0.30-1.34) 0.23 0.613 (0.28-1.30) 0.22 
  Managed Medicare 0.968 (0.83-1.13) 0.68 1.059 (0.90-1.25) 0.50 
  Medicaid 0.596 (0.33-1.08) 0.09 0.384 (0.21-0.72) 0.002 
Charlson Comorbidity Score 0.925 (0.87-0.99) 0.02 0.937 (0.88-0.10) 0.05 
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